Tirzepatide: A dual action approach to weight reduction and glycemic control in type 2 diabetes mellitus
Tirzepatide, a dual GIP and GLP-1 receptor agonist, is an innovative therapy for type 2 diabetes mellitus (T2DM) and obesity. By stimulating insulin secretion, inhibiting glucagon release, slowing gastric emptying, and enhancing satiety, it offers superior glycemic control and weight reduction compa...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2025-01-01
|
| Series: | MGM Journal of Medical Sciences |
| Subjects: | |
| Online Access: | https://doi.org/10.4103/mgmj.mgmj_386_24 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849321334867230720 |
|---|---|
| author | Princy Domnic Dsouza Sai Phalguna Prakash Chitralu Ramish Khan Sanatkumar Bharamu Nyamagoud |
| author_facet | Princy Domnic Dsouza Sai Phalguna Prakash Chitralu Ramish Khan Sanatkumar Bharamu Nyamagoud |
| author_sort | Princy Domnic Dsouza |
| collection | DOAJ |
| description | Tirzepatide, a dual GIP and GLP-1 receptor agonist, is an innovative therapy for type 2 diabetes mellitus (T2DM) and obesity. By stimulating insulin secretion, inhibiting glucagon release, slowing gastric emptying, and enhancing satiety, it offers superior glycemic control and weight reduction compared to conventional GLP-1 receptor agonists. Clinical trials, such as SURPASS and SURMOUNT, have demonstrated their effectiveness in lowering HbA1c and body weight, with potential benefits in conditions like NAFLD, PCOS, and cardiovascular health. While its therapeutic profile is promising, further research is needed to assess its long-term safety, particularly concerning cardiovascular outcomes, gastrointestinal effects, and the risk of medullary thyroid carcinoma (MTC). Its once-weekly administration improves adherence; however, cost and accessibility remain significant challenges. A personalized medicine approach, incorporating biomarker-driven patient selection, may enhance treatment outcomes. As research continues, tripeptide has the potential to revolutionize metabolic disease management. Future studies will clarify its long-term safety, cost-effectiveness, and broader clinical applications. |
| format | Article |
| id | doaj-art-733ceae1240a4e499bb46ff68fef260d |
| institution | Kabale University |
| issn | 2347-7946 2347-7962 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | MGM Journal of Medical Sciences |
| spelling | doaj-art-733ceae1240a4e499bb46ff68fef260d2025-08-20T03:49:46ZengWolters Kluwer Medknow PublicationsMGM Journal of Medical Sciences2347-79462347-79622025-01-0112113614610.4103/mgmj.mgmj_386_24Tirzepatide: A dual action approach to weight reduction and glycemic control in type 2 diabetes mellitusPrincy Domnic DsouzaSai Phalguna Prakash ChitraluRamish KhanSanatkumar Bharamu NyamagoudTirzepatide, a dual GIP and GLP-1 receptor agonist, is an innovative therapy for type 2 diabetes mellitus (T2DM) and obesity. By stimulating insulin secretion, inhibiting glucagon release, slowing gastric emptying, and enhancing satiety, it offers superior glycemic control and weight reduction compared to conventional GLP-1 receptor agonists. Clinical trials, such as SURPASS and SURMOUNT, have demonstrated their effectiveness in lowering HbA1c and body weight, with potential benefits in conditions like NAFLD, PCOS, and cardiovascular health. While its therapeutic profile is promising, further research is needed to assess its long-term safety, particularly concerning cardiovascular outcomes, gastrointestinal effects, and the risk of medullary thyroid carcinoma (MTC). Its once-weekly administration improves adherence; however, cost and accessibility remain significant challenges. A personalized medicine approach, incorporating biomarker-driven patient selection, may enhance treatment outcomes. As research continues, tripeptide has the potential to revolutionize metabolic disease management. Future studies will clarify its long-term safety, cost-effectiveness, and broader clinical applications.https://doi.org/10.4103/mgmj.mgmj_386_24glucagon-like peptide-1 (glp-1)glucose-dependent insulinotropic polypeptide (gip)non-alcoholic fatty liver disease (nafld)obesitypharmacodynamicspharmacokineticspolycystic ovarian syndrome (pcos)tirzepatidetype 2 diabetes mellitus (t2dm) |
| spellingShingle | Princy Domnic Dsouza Sai Phalguna Prakash Chitralu Ramish Khan Sanatkumar Bharamu Nyamagoud Tirzepatide: A dual action approach to weight reduction and glycemic control in type 2 diabetes mellitus MGM Journal of Medical Sciences glucagon-like peptide-1 (glp-1) glucose-dependent insulinotropic polypeptide (gip) non-alcoholic fatty liver disease (nafld) obesity pharmacodynamics pharmacokinetics polycystic ovarian syndrome (pcos) tirzepatide type 2 diabetes mellitus (t2dm) |
| title | Tirzepatide: A dual action approach to weight reduction and glycemic control in type 2 diabetes mellitus |
| title_full | Tirzepatide: A dual action approach to weight reduction and glycemic control in type 2 diabetes mellitus |
| title_fullStr | Tirzepatide: A dual action approach to weight reduction and glycemic control in type 2 diabetes mellitus |
| title_full_unstemmed | Tirzepatide: A dual action approach to weight reduction and glycemic control in type 2 diabetes mellitus |
| title_short | Tirzepatide: A dual action approach to weight reduction and glycemic control in type 2 diabetes mellitus |
| title_sort | tirzepatide a dual action approach to weight reduction and glycemic control in type 2 diabetes mellitus |
| topic | glucagon-like peptide-1 (glp-1) glucose-dependent insulinotropic polypeptide (gip) non-alcoholic fatty liver disease (nafld) obesity pharmacodynamics pharmacokinetics polycystic ovarian syndrome (pcos) tirzepatide type 2 diabetes mellitus (t2dm) |
| url | https://doi.org/10.4103/mgmj.mgmj_386_24 |
| work_keys_str_mv | AT princydomnicdsouza tirzepatideadualactionapproachtoweightreductionandglycemiccontrolintype2diabetesmellitus AT saiphalgunaprakashchitralu tirzepatideadualactionapproachtoweightreductionandglycemiccontrolintype2diabetesmellitus AT ramishkhan tirzepatideadualactionapproachtoweightreductionandglycemiccontrolintype2diabetesmellitus AT sanatkumarbharamunyamagoud tirzepatideadualactionapproachtoweightreductionandglycemiccontrolintype2diabetesmellitus |